These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2953863)

  • 1. HPLC analysis of somatostatin related peptides in putamen of Huntington's disease patients.
    Sperk G; Reynolds GP; Riederer P
    J Neural Transm; 1987; 69(1-2):153-60. PubMed ID: 2953863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease.
    Dawbarn D; De Quidt ME; Emson PC
    Brain Res; 1985 Aug; 340(2):251-60. PubMed ID: 2862959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin is increased in the basal ganglia in Huntington disease.
    Aronin N; Cooper PE; Lorenz LJ; Bird ED; Sagar SM; Leeman SE; Martin JB
    Ann Neurol; 1983 May; 13(5):519-26. PubMed ID: 6191621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Huntington's disease is accompanied by changes in the distribution of somatostatin-containing neuronal processes.
    Marshall PE; Landis DM
    Brain Res; 1985 Mar; 329(1-2):71-82. PubMed ID: 2858256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum of Huntington's disease.
    Norris PJ; Waldvogel HJ; Faull RL; Love DR; Emson PC
    Neuroscience; 1996 Jun; 72(4):1037-47. PubMed ID: 8735228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced density of striatal somatostatin receptors in Huntington's chorea.
    Palacios JM; Rigo M; Chinaglia G; Probst A
    Brain Res; 1990 Jul; 522(2):342-6. PubMed ID: 1977497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoreactive somatostatin-28(1-12) is increased in Huntington's disease.
    Beal MF; Benoit R; Bird ED; Martin JB
    Neurosci Lett; 1985 May; 56(3):377-80. PubMed ID: 2862613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease.
    De Souza EB; Whitehouse PJ; Folstein SE; Price DL; Vale WW
    Brain Res; 1987 Dec; 437(2):355-9. PubMed ID: 2893655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptides derived from prodynorphin are decreased in basal ganglia of Huntington's disease brains.
    Dawbarn D; Zamir N; Waters CM; Hunt SP; Emson PC; Brownstein MJ
    Brain Res; 1986 Apr; 372(1):155-8. PubMed ID: 2871898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased muscarinic receptor concentration in post-mortem brain in Huntington's chorea.
    Hiley CR; Bird ED
    Brain Res; 1974 Nov; 80(2):355-8. PubMed ID: 4278580
    [No Abstract]   [Full Text] [Related]  

  • 11. Somatostatin is increased in the nucleus accumbens in Huntington's disease.
    Beal MF; Bird ED; Langlais PJ; Martin JB
    Neurology; 1984 May; 34(5):663-6. PubMed ID: 6143284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease.
    Beal MF; Mazurek MF; Ellison DW; Swartz KJ; McGarvey U; Bird ED; Martin JB
    Ann Neurol; 1988 Jun; 23(6):562-9. PubMed ID: 2900622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease.
    Huang Q; Zhou D; Sapp E; Aizawa H; Ge P; Bird ED; Vonsattel JP; DiFiglia M
    Neuroscience; 1995 Mar; 65(2):397-407. PubMed ID: 7777157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional distribution of methionine-enkephalin and substance P-like immunoreactivity in normal human brain and in Huntington's disease.
    Emson PC; Arregui A; Clement-Jones V; Sandberg BE; Rossor M
    Brain Res; 1980 Oct; 199(1):147-60. PubMed ID: 6157454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin 1-12 immunoreactivity is decreased in the hypothalamic lateral tuberal nucleus of Huntington's disease patients.
    Timmers HJ; Swaab DF; van de Nes JA; Kremer HP
    Brain Res; 1996 Jul; 728(2):141-8. PubMed ID: 8864475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benzodiazepine and GABA receptors in early Huntington's disease.
    Walker FO; Young AB; Penney JB; Dovorini-Zis K; Shoulson I
    Neurology; 1984 Sep; 34(9):1237-40. PubMed ID: 6087209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D-1 and D-2 receptors in Huntington's disease.
    Cross A; Rossor M
    Eur J Pharmacol; 1983 Mar; 88(2-3):223-9. PubMed ID: 6221936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin immunoreactivity in cortical and some subcortical regions in Alzheimer's disease.
    Candy JM; Gascoigne AD; Biggins JA; Smith AI; Perry RH; Perry EK; McDermott JR; Edwardson JA
    J Neurol Sci; 1985 Dec; 71(2-3):315-23. PubMed ID: 2868073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain.
    Reynolds GP; Pearson SJ
    Neurosci Lett; 1987 Jul; 78(2):233-8. PubMed ID: 2442679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What excitotoxin kills striatal neurons in Huntington's disease? Clues from neurochemical studies.
    Perry TL; Hansen S
    Neurology; 1990 Jan; 40(1):20-4. PubMed ID: 1967491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.